{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:07:04Z","timestamp":1790654824436,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaad.2021.01.024","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T16:22:01Z","timestamp":1611073321000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"I-Hsin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chih","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsiu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jaad.2021.01.024_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The concept of psoriasis as a systemic inflammation: implications for disease management","volume":"26","author":"Reich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2021.01.024_bib2","first-page":"1","article-title":"Nail psoriasis as a severity indicator: results from the PsoReal study","volume":"2","author":"Radtke","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000246274","article-title":"Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients","volume":"193","author":"de Jong","year":"1996","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","article-title":"Nail psoriasis in Germany: epidemiology and burden of disease","volume":"163","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.01.024_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000182250","article-title":"The nail as a musculoskeletal appendage\u2014implications for an improved understanding of the link between psoriasis and arthritis","volume":"218","author":"McGonagle","year":"2009","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2021.01.024_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","article-title":"Extended report: nail disease in psoriatic arthritis\u2014clinically important, potentially treatable and often overlooked","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib7","first-page":"203","article-title":"Nail psoriasis\u2014a treatment challenge","volume":"11","author":"Radtke","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.01.024_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2021.01.024_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","article-title":"Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Crowley","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.01.024_bib13","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13555-019-00337-y","article-title":"Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses","volume":"10","author":"Warren","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib15","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.jaad.2021.01.024_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2021.01.024_bib17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2021.01.024_bib18","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"issue":"7109","key":"10.1016\/j.jaad.2021.01.024_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaad.2021.01.024_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"7-8","key":"10.1016\/j.jaad.2021.01.024_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jaad.2021.01.024_bib23","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.01.024_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2133.1970.tb02205.x","article-title":"Fingernail growth in normal and psoriatic subjects","volume":"82","author":"Dawber","year":"1970","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.01.024_bib26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9494","key":"10.1016\/j.jaad.2021.01.024_bib27","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"13","key":"10.1016\/j.jaad.2021.01.024_bib31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2021.01.024_bib32","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jaad.2021.01.024_bib33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.12229","article-title":"Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study","volume":"40","author":"Ozmen","year":"2013","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.01.024_bib34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jdv.12198","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: post hoc analysis of REACH","volume":"28","author":"Poulin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.01.024_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.01.024_bib37","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.01.024_bib39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.01.024_bib42","article-title":"Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 24-week data from a phase 3 trial","author":"Ghislain","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.01.024_bib43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"10.1016\/j.jaad.2021.01.024_bib45","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2021.01.024_bib46","first-page":"74","article-title":"Secukinumab provides rapid and sustained reductions in dactylitis, enthesitis, and nail psoriasis in patients with psoriatic arthritis (PsA)","volume":"58","author":"Nash IBM","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2021.01.024_bib50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/annrheumdis-2016-eular.5018","article-title":"FRI0460 secukinumab shows significant efficacy in nail psoriasis: week 32 results from The Transfigure Study","volume":"75","author":"Reich","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"van de Kerkhof","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2021.01.024_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2021.01.024_bib53","article-title":"Improvement in scalp and nails with apremilast in patients with moderate plaque psoriasis naive to systemic and biologic therapy: 52-week results of the UNVEIL study","author":"Jackson","year":"2018","journal-title":"MauiDerm Dermatolog"},{"issue":"9","key":"10.1016\/j.jaad.2021.01.024_bib54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.01.024_bib55","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.01.024_bib56","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/jdv.15793","article-title":"Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.01.024_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.01.024_bib58","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/acr.23905","article-title":"Efficacy and safety of intravenous golimumab through one year in patients with active psoriatic arthritis","volume":"72","author":"Husni","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.jaad.2021.01.024_bib59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-3083.2010.03938.x","article-title":"Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)","volume":"25","author":"Sanchez-Regana","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.2013.736960","article-title":"TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis","volume":"13","author":"Saraceno","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2021.01.024_bib61","first-page":"1065","article-title":"A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis","volume":"11","author":"Bardazzi","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jaad.2021.01.024_bib62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09546634.2011.646939","article-title":"Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study","volume":"24","author":"Kyriakou","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2021.01.024_bib63","first-page":"97","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"9","key":"10.1016\/j.jaad.2021.01.024_bib65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/rheumatology\/33.9.834","article-title":"Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease","volume":"33","author":"Jones","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.01.024_bib66","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.16497","article-title":"Ixekizumab or secukinumab in psoriasis: what difference does it make?","volume":"178","author":"Paul","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.01.024_bib67","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2021.01.024_bib68","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2021.01.024_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-3083.2009.03426.x","article-title":"Growth rate of human fingernails and toenails in healthy American young adults","volume":"24","author":"Yaemsiri","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221001687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221001687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T23:25:29Z","timestamp":1724801129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221001687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0190962221001687"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}